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Summary
 Background Anaplastic oligodendrogliomas (AO) are infi ltrative, mostly supratentorial tu-
mours, often bilaterally affecting the white matter. Radiotherapy alone or in com-
bination with chemotherapy have a role in the adjuvant treatment of AO, but 
currently the effi cacy of various treatment modalities could not be defi nitively 
determined because of the heterogeneity of the therapies used.
 Aim Assessment of the effi cacy of altered therapy schedules in postoperative treat-
ment of patients with anaplastic oligodendrogliomas
 Materials/Methods Between 1975 and 2000, 101 adult patients with anaplastic oligodendrogliomas 
were postoperatively treated in our institution. During this period patients re-
ceived conventional radiation therapy and chemotherapy (CRT/CH), conven-
tional radiation therapy (CRT), and split course hypofractionated radiation ther-
apy (SCHRT).
  Between 1975 and 1985, CRT/CH was applied in 42 patients. Whole brain irra-
diation was delivered; the tumour dose of 5Gy in 25 fractions over 5 weeks was 
calculated at the midplane of the skull. Then treatment fi elds were reduced and 
a 10Gy boost was given in 5 fractions over 5 days to the known tumour bearing 
area. On the last day of irradiation patients began the fi rst of six planned series 
of chemotherapy with CCNU, given 100mg/2, orally every 8 weeks. From 1986 to 
1990, CRT was received by 27 patients. Irradiation was only as described above. 
Between 1991 and 2000, 32 patients were given SCHRT. There were 3 courses of 
irradiation separated by a one-month interval. In each of the two fi rst series pa-
tients received 20Gy in 5 fractions in fi ve days to the whole brain, and in the third 
course a 20Gy boost in 5 fractions over 5 days was given as in the CRT regimen.
 Results Actuarial overall survival rates at two and fi ve years were 38% and 10% respective-
ly for patients treated with CRT/CH, 36% and 11% for the CRT group, and 23% 
and 6% for the SCHRT option. Multivariate analysis revealed that only age was a 
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BACKGROUND
Approximately 5% of all primary brain tumours 
are of oligodendroglial tissue. The anaplastic var-
iant, representing about 30% of all oligodendro-
gliomas, is a markedly densely cellular tumour 
with pleomorphic nuclei, frequent mitotic activi-
ty, vascular proliferation and occasional giant cells. 
According to the WHO classifi cation, the detec-
tion of necrosis in an anaplastic oligodendroglial 
tumour per se does not make it a glioblastoma. The 
exact delineation of low- and high-grade (anaplas-
tic) oligodendroglioma is somewhat unclear. The 
diagnosis of oligodendroglioma is based on histo-
logical verifi cation of a tumour sample. In addition 
to histological analysis, fl uorescent in situ hybridi-
zation (FISH) or loss of heterozygosity (LOH) to 
detect losses on 1p or 19q may be added to make 
the diagnosis. It should be admitted at this point, 
however, that fi nal diagnosis as defi ned by WHO 
does not yet include these molecular properties. 
Anaplastic oligodendrogliomas (AO) are infi ltra-
tive, mostly supratentorial tumours which frequent-
ly originate in the frontal lobes (50%), often bilat-
erally affecting the white matter. Corpus callosum 
and basal ganglia may also be involved [1,2].
Radiotherapy alone or in combination with chem-
otherapy have a role in the adjuvant treatment 
of AO, but currently the effi cacy of various treat-
ment modalities could not be defi nitively deter-
mined because of the heterogeneity of the ther-
apies used [3].
AIM
The objective of this study is to evaluate the effi -
cacy of altered therapy schedules in the postop-
erative management of patients with AO.
MATERIALS AND METHODS
Patients
The study population was derived from neurosur-
gical centres which referred patients to the Maria 
Sklodowska-Curie Memorial Centre in Kraków. 
Surgery consisted of as complete tumour removal 
as was feasible. All surgical specimens were eval-
uated by the same pathologist according to the 
WHO classifi cation. The diagnosis of AO was 
made based on histological criteria including the 
presence of oligodendroglial morphology, hyper-
cellularity, nuclear pleomorphism and mitotic ac-
tivity [4]. Low-grade oligodendrogliomas and an-
aplastic mixed gliomas were excluded.
Methods
Between 1975 and 2000, 101 adult patients with 
AO were treated according to one of the three 
protocols used at our institution. During this pe-
riod, the treatment modalities were as follows: 
conventional radiation therapy and chemother-
apy (CRT-CH), conventional radiation therapy 
(CRT), and split course hypofractionated radia-
tion therapy (SCHRT).
Megavoltage irradiation (Cobalt-60 unit or line-
ar accelerator) was started from four to six weeks 
after surgery.
Between 1975 and 1985 CRT/CH was applied. 
Whole brain irradiation delivered to a tumour 
dose of 50Gy in 25 fractions over 5 weeks was 
calculated at the midplane of the skull. Then, 
the treatment fi elds were reduced to cover the 
known tumour bearing area and a 10Gy “boost” 
was given in 5 fractions over 5 days. On the last 
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 Conclusions The effi cacy of different postoperative treatments administered to our patients 
with anaplastic oligodendrogliomas gave approximately comparable and unre-
warding poor results.
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day of irradiation , patients began the fi rst of the 
six series of chemotherapy. CCNU was given 
100mg/m2, orally every 8 weeks.
1986–1990, CRT: irradiation only as described 
above.
1991–2000 SCHRT: there were 3 courses of irradi-
ation separated by a one-month interval. In each 
of the two fi rst series patients received 20Gy in 5 
fractions over 5 days to the whole brain, and in 
the third course a 20Gy “boost” in 5 fractions over 
5 days was given as in the CRT regimen.
Patients’ characteristics by treatment option are 
presented in Table 1.
There was some disparity between the charac-
teristics of patients with more frontal tumours 
and relatively more partial resections in the CRT 
group. On the basis of the fi nal results of multi-
variate analysis, it was confi rmed that these two 
parameters (extent of surgery and tumour loca-
tion) did not affect patient’s survival.
Supportive treatment
Systemic anticonvulsants (phenytoine or pheno-
barbital) were administered to all patients dur-
ing irradiation. Steroids were given only as symp-
tomatic medication required to control cerebral 
oedema.
Statistical methods
At the time of this analysis, 90 of 101 patients 
were known to have died. Estimates of survival 
were obtained by the product-limit method of 
Kaplan-Meier and comparisons were made by 
the log-rank test [5,6]. Both univariate and mul-
tivariate analyses were performed in order to de-
tect prognostic factors, using the Cox proportion-
al hazards model. The results are expressed as a 
hazard ratio with a 95% confi dence interval [7]. 
The following prognostic variables were studied: 
age, gender, tumour location, extent of surgery, 
Karnofsky status (KS) and treatment schedule.
RESULTS
Tolerance of irradiation
The tolerance was assessed according to the follow-
ing criteria: very good – treatment without com-
plications; good – periodic symptoms of increased 
intracranial pressure controlled pharmacological-
ly with no breaks in irradiation; poor – the above 
symptoms which caused breaks in irradiation or its 
discontinuation. Radiotherapy was generally well 
tolerated; skin reactions in the SCHRT group were 
reported to be no more severe than those of the 
CRT regimen. Table 2 presents tolerance of irra-
diation according to treatment option.
Survival
Survival by treatment option is given in Figure 1.
Characteristics CRT/CH CRT SCHRT
Number of patients 42 27 32
Gender
 Male  25 (59%)  17 (63%)  21 (65%)
 Female  17 (41%)  10 (37%)  11 (35%)
Age (years) 
 45 and less  23 (55%)  13 (48%)  13 (41%)
 More then 45  19 (45%)  14 (52%)  19 (59%)
Surgery 
 Partial resection  29 (69%)  21 (78%)  22 (68%)
 Total resection  13 (31%)  6 (22%)  10 (32%)
Tumor location
 Frontal  19 (46%)  10 (37%)  17 (53%)
 Temporal  12 (28%)  8 (30%)  8 (25%)
 Elsewhere  11 (26%)  9 (33%)  7 (22%)
Karnofsky’s status
 More than 60%  28 (66%)  21 (77%)  23 (72%)
 60%  14 (34%)  6 (23%)  9 (28%)
Table 1. Patient characteristics by the treatment option.
CRT/CH – conventional radiotherapy and chemotherapy;







Very good  35 (84%)  22 (81%)  29 (91%)
Good  4 (9%)  4 (15%)  2 (6%)
Poor  3 (7%)  1 (4%)  1 (3%)
Table 2. Tolerance according to treatment schedule.
CRT/CH – conventional radiotherapy and chemotherapy;
CRT – conventional radiotherapy; SCHRT – split course hypofra-
ctionated radiotherapy.
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The overall actuarial survival rates at 5 years in 
CRT/CH, CRT and SCHRT treatment groups were 
10%, 11% and 6% respectively. The differences be-
tween survivals were not statistically signifi cant.
In Tables 3 and 4, univariate analysis of prog-
nostic factors and the defi nitive Cox model are 
presented.
DISCUSSION
Our observations of clinical population features 
of patients with AO are similar to those report-
ed by other authors. The majority of patients 
were in the fi fth and sixth decades of age and 
the most common site of tumour was the fron-
tal lobe [8–10].
Our results are comparable to those described 
in the literature (Tables 5 and 6).
Numerous prognostic factors have been reported 
for AO, such as age, gender, performance status, 
neurological function, tumour location, extent 
of primary surgery, postoperative radiotherapy 
and/or chemotherapy, and molecular alterations, 
but no consensus has been obtained.
In our group of 101 patients with AO, only age 
was found to be an independent prognostic fac-
tor in determining overall survival. A better out-
come in younger patients was reported in oth-
er series [8,11,12,13]. It is known that brain 
tumours in elderly patients seem to have an in-
trinsic resistance to cancer treatment; however, 
there is no clear explanation for this fact. The 
brain may have a unique role in the process of 
ageing; differentiated post-mitotic neurons are 
not replaced by cell division, and little turnover 
of DNA occurs in glial cells. Moreover, cell aging 
in the brain may be associated with a decrease in 
oxygen uptake. This may be related to the lower 
number of cytotoxic free radicals during irradi-
ation, or to the difference existing in scavenging 




























Figure 1. Survival by treatment option.
Factors MST p
Age (years)
 45 or less 51
 More than 45 16 0.0016
Gender
 Male 25
 Female 23 NS
Tumour location
 Frontal 24
 Elsewhere 18 NS
Surgery
 Total resection 30
 Partial resection 20 NS
Karnofsky’s status
 More than 60% 30




 SCHRT 30 NS
Table 3. Univariate analysis of prognostic factors. 
MST – median survival time in months; NS – statistically 
non-significant; CRT/CH – conventional radiotherapy and 
chemotherapy; CRT – conventional radiotherapy; SCHRT – split 
course hypofractionated radiotherapy.
Factors HR CR 95% p
Age (years)
 45 or less 1
 More than 45 3.06 1.89–4.30 0.0000
Surgery
 Total resection 1
 Partial resection 1.9 1.15–1.23 0.0624 (NS)
Table 4. The defi nitive Cox model.
HR – hazard ratio; CR – confidence interval; NS – non-
signifi cant.
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molecules [14]. Rosenblum et al. have shown 
that patient’s age was inversely correlated with in 
vitro cell kill from a biopsy, and patients with sen-
sitive cells were signifi cantly younger than those 
with resistant cells [15]. Older people may have 
accumulated genetic damage throughout their 
lives, which is linked to exposure to exogenous 
mutagens and a possible decrease in various host 
functions, such as DNA repair and other defence 
mechanisms in normal tissues [16]. An attempt 
has been made to explain favourable diagnosis 
in younger patients by better tolerance of treat-
ment, surgery as well as radiotherapy [17].
The extent of surgical resection has been reported 
to correlate with survival in patients with malignant 
gliomas. In our population composed of AO only 
patients, there was a trend toward longer survival 
with greater extent of resection, although the ben-
efi ts of surgery did not reach statistical signifi cance. 
The role of surgical resection in the management 
of patients with malignant gliomas remains contro-
versial, despite the prospective randomized stud-
ies of BTSG demonstrating a signifi cant impact of 
extent of surgery on median survival, even when 
adjusted for age, histology and performance sta-
tus [18]. Based on our own experience we think 
that the impact of extent of surgery is diffi cult to 
ascertain due to the inadequate terminology used 
in surgical reports, which very often does not cor-
relate with postoperative CT scan.
Gender and tumour location did not signifi cant-
ly affect survival in the present series. The infl u-
ence of these factors in patients with AO has not 
been clearly established [3,8,9,19].
The Karnofsky performance status and parame-
ters of neurological function did not signifi cantly 
affect survival in our material. Besides, compar-
ison of our results with others is diffi cult due to 
differences in the criteria used for assessment of 
neurological status. The same problem applies 
to performance status. In many series, neurolog-
ical functional grade and/or Karnofsky score are 
important variables which have an impact on the 
survival time of patients [3,8,20–22]. On the oth-
er hand, there are reports which did not fi nd any 
signifi cant impact of these factors [9,12,19].The 
neurological status appears to be a better predic-
tor than performance status. Assessment of status 
in patients with brain tumours by the Karnofsky 
score or WHO scale seems to be insuffi cient com-
pared with neurological function. The neurolog-
ical status can probably be more precise than the 
performance status, which is assessed second to 
neurological function.
Standard treatment for AO consists of maximum 
surgical resection and radiotherapy [1,3,9,12,13]. 
In the early 1990s it was recognized that some 
patients with these tumours demonstrated good 
response to systemic chemotherapy, particular-
ly to the PCV (procarbazine, lomustine and vin-
cristine) regimen [10,19–21,23]. This observa-
tion prompted two phase III trials. In the fi rst 
(RTOG 9402) patients with AO were randomly 
assigned to receive either radiation therapy or up 
to 4 cycles of the PCV regimen followed by irra-
diation. In the second (EORTC 26951) patients 
were randomized to radiation therapy only, or to 
the same radiotherapy followed by six cycles of 
PCV chemotherapy. Both studies showed nearly 
identical results. They demonstrated no overall 
survival benefi t when chemotherapy was added 
[10,24]. The two studies described above have not 
defi ned the standard fi rst line treatment for pa-
tients with AO. Both approaches – the early use 
Author N MST
Kryitsis et al. 1993 [11] 20 51
Kros 1994 et al. 1994 [12] 62 17
Kim et al. 1996 [13] 32 40
Deghani  et al. 1998 [14] 24 12
Jeremic et al. 1999 [15] 18 36
Vanden Bent et al. 2006 [10] 185 40
Present series 42 35
Table 5. Results of postoperative irradiation and chemotherapy 
of anaplastic oligodendrogliomas.
MST – median survival time in months.
Author N MST
Smith et al. 1983 [16] 23 17
Mork et al. 1985 [17] 26 17
Shaw et al. 1992 [18] 55 38
Donahue et al. 1997 [19] 91 41
Paleoglos et al. 1999 [9] 36 27
Present series 27 25
Table 6. Results of postoperative conventional irradiation of 
anaplastic oligodendrogliomas.
MST – median survival time in months.
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of chemotherapy along with radiation treatment 
or waiting for tumour recurrence to start chemo-
therapy, thereby delaying the toxicities associated 
with these treatment regimens – should be con-
sidered acceptable. Determination of the pres-
ence or absence of 1p and 19q LOH (allelic loss 
of heterozygosity) should be mandatory because 
this fi nding has now been proven to have impor-
tant prognostic and predictive power [13].
In our group of patients with AO, addition of 
chemotherapy with lomustine to the postopera-
tive irradiation did not infl uence survival, but no 
defi nite conclusions regarding treatment effi cacy 
can be drawn from the presented data. This study 
was done over a period of three decades during 
which changes in diagnostic techniques and clin-
ical management were inevitable. Bias could be 
introduced by such factors and by the heteroge-
neity of treatment used in the described period, 
making it diffi cult to determine the true effi cacy 
of the three presented treatment regimens.
CONCLUSIONS
The three different regimens used in our insti-
tution in the postoperative management of pa-
tients with anaplastic oligodendrogliomas were 
well tolerated. Conventionally fractionated radi-
otherapy with adjuvant chemotherapy provided 
approximately the same survival rates as radia-
tion therapy alone, with overall fi ve year surviv-
al of 10% and 11% respectively.
We do not recommend split course hypofraction-
ated radiotherapy for these patients.
Age is the most important prognostic factor 
which signifi cantly infl uences overall survival. 
Patients aged 45 years and less carried the best 
prognosis.
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